C000203168 Performance — EQ/T. Rowe Price Health Sciences Portfolio, Class IB
Data updated: 2026-08-25
C000203168 returned +7.27% year to date and +32.05% over one year to Jun 2026. Annualised returns are +9.97% over 3 years and +3.56% over 5 years. The fund trailed its Health Care Equity category average: $100 invested three years ago grew to $133, against $138 for the category, and to $132 over one year, against $137. Volatility over the past three years was 15.87% a year. In the 12 months to Jun 2026 the fund lost a net $19.3M, and assets reached $176.60M.
C000203168 Growth of $100
What $100 invested in EQ/T. Rowe Price Health Sciences Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | C000203168 | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $132 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $133 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $119 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $179 | $182 |
C000203168 Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +7.27% |
| 1 year | +32.05% |
| 3 years (annualised) | +9.97% |
| 5 years (annualised) | +3.56% |
C000203168 Annual Returns
Calendar-year total returns of EQ/T. Rowe Price Health Sciences Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +7.27% |
| 2025 | +19.21% |
| 2024 | +1.58% |
| 2023 | +3.97% |
| 2022 | −13.38% |
| 2021 | +9.51% |
| 2020 | +26.91% |
| 2019 (Jul–Dec) | +9.86% |
C000203168 Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −1.0% | +0.8% | −6.0% | +1.6% | +3.5% | +8.8% | — | — | — | — | — | — |
| 2025 | +6.2% | −2.2% | −4.5% | +0.1% | −6.3% | +4.1% | −1.0% | +4.1% | +2.6% | +8.5% | +9.5% | −2.0% |
| 2024 | +2.1% | +4.4% | +1.5% | −5.6% | +2.3% | +3.0% | +3.1% | +4.9% | −2.0% | −4.8% | +1.4% | −7.8% |
| 2023 | +0.9% | −5.0% | +1.9% | +3.6% | −2.7% | +3.1% | 0.0% | −1.7% | −4.2% | −4.4% | +6.1% | +7.2% |
| 2022 | −13.0% | −0.7% | +4.9% | −9.2% | −1.3% | −0.5% | +6.1% | −3.2% | −4.4% | +7.9% | +4.3% | −2.9% |
| 2021 | +2.0% | −1.9% | −1.3% | +4.9% | −1.2% | +5.2% | +1.7% | +4.0% | −5.3% | +3.9% | −5.1% | +3.1% |
| 2020 | −2.7% | −4.7% | −6.9% | +14.2% | +7.6% | +0.5% | +3.2% | +1.6% | +1.2% | −1.4% | +9.3% | +4.0% |
| 2019 | — | — | — | — | — | — | −1.4% | −2.9% | −3.7% | +6.6% | +8.6% | +2.9% |
C000203168 Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 15.87%
- 3-year Sharpe ratio: 0.34 (vs 4.5% risk-free rate)
- Best month: +9.45% (Nov 2025)
- Worst month: −7.83% (Dec 2024)
C000203168 Fund Flows
Monthly money in and out of EQ/T. Rowe Price Health Sciences Portfolio, from SEC Form N-PORT.
- 12-month net flow: −$19.3M
- 12-month gross sales (incl. reinvestments): $15.8M
- Sales ÷ redemptions: 0.45×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $1.6M | $2.4M | −$766K |
| May 2026 | $861K | $2.8M | −$1.9M |
| Apr 2026 | $756K | $2.8M | −$2.0M |
| Mar 2026 | $1.1M | $2.3M | −$1.2M |
| Feb 2026 | $623K | $2.9M | −$2.3M |
| Jan 2026 | $530K | $3.6M | −$3.0M |
| Dec 2025 | $1.9M | $4.0M | −$2.0M |
| Nov 2025 | $916K | $2.8M | −$1.9M |
| Oct 2025 | $2.7M | $3.3M | −$615K |
| Sep 2025 | $2.2M | $2.8M | −$638K |
| Aug 2025 | $1.4M | $2.6M | −$1.2M |
| Jul 2025 | $1.1M | $2.8M | −$1.7M |
C000203168 Assets Under Management
Net assets of EQ/T. Rowe Price Health Sciences Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $176.60M |
| 2026-03-31 | $158.96M |
| 2025-12-31 | $176.15M |
| 2025-09-30 | $158.06M |
| 2025-06-30 | $152.81M |
| 2025-03-31 | $159.95M |
| 2024-12-31 | $164.28M |
| 2024-09-30 | $188.70M |
| 2024-06-30 | $185.08M |
| 2024-03-31 | $190.20M |
| 2023-12-31 | $183.58M |
| 2023-09-30 | $172.60M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.